A New RNA Strategy Could Target Thousands of Genetic Disorders

University of Toronto researchers designed an engineered transfer RNA (tRNA) that bypasses nonsense mutations causing premature stop signals in protein production. In tissue from a cystic fibrosis patient unresponsive to existing drugs, the tRNA combined with the drug Trikafta restored full-length protein production; in human airway cells with two common nonsense mutations, the restored protein functioned normally for over 40 days.

These are laboratory and preclinical models; translation to clinical use in patients requires further research and testing.